Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Pharmaron Beijing Co., Ltd.

康龍化成(北京)新藥技術股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 3759)

(I) POLL RESULTS OF THE ANNUAL GENERAL MEETING OF 2025; (II) THE 2025 PROFIT DISTRIBUTION PLAN; (III) ELECTION AND APPOINTMENT OF DIRECTORS OF THE FOURTH SESSION OF THE BOARD; AND (IV) AMENDMENTS TO THE ARTICLES OF ASSOCIATION

The Board of Directors (the "**Board**") of Pharmaron Beijing Co., Ltd. (the "**Company**") is pleased to announce that the Annual General Meeting of 2025 (the "**AGM**") of the Company was held at Juhui Hall, 5/F, Block B, Zhaolin Plaza, No. 19 Ronghua Middle Road, Beijing Economic and Technological Development Area, Daxing District, Beijing, the PRC on June 12, 2026, and all the resolutions set out below were voted by way of poll.

References are made to the notice of the AGM (the "**Notice**") and the circular (the "**Circular**") of the Company dated May 21, 2026. Unless otherwise defined, terms used herein shall have the same meanings as those defined in the Circular.

(I) POLL RESULTS OF THE AGM HELD ON JUNE 12, 2026

As at the date of the AGM, the total number of issued shares of the Company (the "**Shares**") is 1,830,020,328 Shares (comprising 1,477,305,741 A Shares and 352,714,587 H Shares (excluding any treasury H Shares)). On the day of the AGM, the Company held 7,263,300 treasury H Shares. Hence, the holders of these treasury Shares must abstain from voting at the AGM. Consequently, the actual number of Shares which gave rise to voting rights at the AGM was 1,830,020,328 Shares.

The AGM was legally and validly convened in compliance with the requirements of the PRC Company Law and the Articles of Association. The chairman of the AGM was Dr. LOU Boliang, the Chairman of the Board.

In compliance with the requirements of the Listing Rules, the Company appointed Tricor Investor Services Limited (the Company's H Share Registrar), the Company's shareholder representatives and Zhong Lun Law Firm (the Company's PRC Legal Adviser) as the scrutineers for the vote-taking at the AGM.

At the time of the AGM, all Directors (including executive Directors Dr. LOU Boliang, Mr. LOU Xiaoqiang and Ms. ZHENG Bei, employee representative Director Mr. LI Shing Chung Gilbert, non-executive Directors Mr. LI Jiaqing and Ms. WAN Xuan, and independent non-executive Directors Ms. LI Lihua, Mr. YU Jian and Prof. TSANG King Fung) attended the AGM.

1. CONVENING OF AGM

The total number of Shares entitling the holders to attend and vote in respect of the respective resolutions at the AGM is 1,830,020,328 Shares (excluding 7,263,300 treasury H Shares).

Save as disclosed above, no Shareholder of the Company was required under Rule 13.40 of the Listing Rules to abstain from voting in favor of any of the resolutions at the AGM. No Shareholder was required under the Listing Rules to abstain from voting. No Shareholders have stated their intention in the Circular to vote against or to abstain from voting on the relevant resolution.

The total number of Shares with voting rights represented by the Shareholders attending the AGM in person or by proxy was 891,123,551, representing approximately 48.6947% of the total number of Shares with voting rights.

2. POLL RESULTS OF AGM

The poll results in respect of the respective resolutions at the AGM were as follows:

ORDINARY RESOLUTIONS (NON-CUMULATIVE VOTING)		FOR		AGAINST		ABSTAIN	
		NUMBER OF VOTES (SHARES)	PERCENTAGE	NUMBER OF VOTES (SHARES)	PERCENTAGE	NUMBER OF VOTES (SHARES)	PERCENTAGE
1.	Work Report of the Board for the Year 2025.	888,825,826	99.7422%	1,877,525	0.2107%	420,200	0.0472%
2.	2025 Profit Distribution and 2026 Interim Dividend Plan.	889,047,526	99.7670%	1,706,325	0.1915%	369,700	0.0415%
3.	2025 Annual Report's full text and report summary and 2025 Annual Results Announcement.	888,939,626	99.7549%	1,765,925	0.1982%	418,000	0.0469%
4.	Remuneration of the Directors for the Year 2026.	888,593,026	99.7160%	2,173,425	0.2439%	357,100	0.0401%
5.	Adoption of the Remuneration Management Policy for Directors and Senior Management.	888,770,226	99.7359%	1,972,625	0.2214%	380,700	0.0427%
6.	Estimated Hedging Quota for the Year 2026.	888,934,226	99.7543%	1,811,125	0.2032%	378,200	0.0424%
7.	Engagement of Domestic Financial and Internal Control Auditors for the Year 2026.	885,871,779	99.4107%	4,866,972	0.5462%	384,800	0.0432%
8.	Engagement of International Auditor for the Year 2026.	886,045,079	99.4301%	4,690,672	0.5264%	387,800	0.0435%
9.	Appointment of Non-executive Director of the Fourth Session of the Board.	886,618,556	99.4945%	4,127,995	0.4632%	377,000	0.0423%

ORDINARY RESOLUTIONS (CUMULATIVE VOTING)		Cumulative Votes	
		NUMBER OF VOTES (SHARES)	PERCENTAGE
10.	Appointment of Executive Directors of the Fourth Session of the Board:		
	10.1 Appointment of Dr. LOU Boliang as an executive director of the Company;	761,855,533	85.4938%
	10.2 Appointment of Mr. LOU Xiaoqiang as an executive director of the Company; and	754,308,269	84.6469%
	10.3 Appointment of Ms. ZHENG Bei as an executive director of the Company.	790,264,601	88.6818%
11.	Appointment of Independent Non-executive Directors of the Fourth Session of the Board:		
	11.1 Appointment of Ms. LI Lihua as an independent non-executive director of the Company;	790,163,169	88.6704%
	11.2 Appointment of Prof. TSANG King Fung as an independent non-executive director of the Company; and	797,084,339	89.4471%
	11.3 Appointment of Ms. SHEN Rong as an independent non-executive director of the Company.	797,117,105	89.4508%

SPECIAL RESOLUTIONS (NON-CUMULATIVE VOTING)		FOR		AGAINST		ABSTAIN	
		NUMBER OF VOTES (SHARES)	PERCENTAGE	NUMBER OF VOTES (SHARES)	PERCENTAGE	NUMBER OF VOTES (SHARES)	PERCENTAGE
12.	Estimated External Guarantees Quota for the Year 2026.	888,668,551	99.7245%	2,062,025	0.2314%	392,975	0.0441%
13.	Grant of General Issuance Mandate.	810,645,944	90.9690%	80,119,075	8.9908%	358,532	0.0402%
14.	Increase in the Registered Capital.	888,956,451	99.7568%	2,086,125	0.2341%	80,975	0.0091%
15.	Amendments to the Articles of Association.	888,971,951	99.7586%	1,763,025	0.1978%	388,575	0.0436%

Notes:

1. For the purpose of calculating the result of the resolutions, all the votes for, against and abstain shall be regarded as voting rights.

2. Any discrepancies in the table between the total and the sum of the amounts listed are due to rounding.

3. Please refer to the Circular for a full text of the resolutions.

The ordinary resolutions Nos. 1 to 11 above were passed by the affirmative votes representing more than half of the total number of Shares held by the attending Shareholders having voting rights who attended the AGM in person or by proxy. These resolutions were duly passed as ordinary resolutions of the Company.

The special resolutions Nos. 12 to 15 above were passed by the affirmative votes representing more than two-thirds of the total number of Shares held by the attending Shareholders having voting rights who attended the AGM in person or by proxy. These resolutions were duly passed as special resolutions of the Company.

As of the date of the AGM, the total number of Shares issued by the Company (excluding any treasury H Shares) was 1,830,020,328. The General Issuance Mandate under the special resolution No. 13 will be determined with reference to such number of Shares accordingly.

(II) 2025 PROFIT DISTRIBUTION PLAN

The Board announces the following information relating to the 2025 Profit Distribution Plan:

The Company will distribute in the form of cash dividends on Wednesday, July 15, 2026 (the "**Record Date**"), RMB0.2 (tax inclusive) (the "**Current Final Dividend**") for every 1 Share to all Shareholders, amounting to approximately RMB366.0 million (tax inclusive) in aggregate. If the total share capital of the Company changes from the date of AGM (i.e. June 12, 2026) to the Record Date for the implementation of profit distribution, the Company intends to maintain each share distribution amount unchanged and adjust the total distribution amount accordingly. For information including equity on the relevant record date and registration date for A Shareholders, please refer to the relevant announcements published on the Shenzhen Stock Exchange by the Company.

In accordance with the Articles of Association, dividends shall be denominated and declared in RMB and payable in RMB to A Shareholders and HK$ to H Shareholders. The actual amount declared in HK$ is calculated based on the average exchange rate of HK$ against RMB as promulgated by the People's Bank of China for the five business days preceding the date of the AGM (HK$1 against RMB0.869840).

The Company appointed CMB Wing Lung Bank as the receiving agent (the "**Receiving Agent**") which will receive the Current Final Dividend declared by the Company on behalf of the H Shareholders. The Current Final Dividend will be paid by the Receiving Agent and the dividend warrants will be posted by the H Share Registrar, Tricor Investor Services Limited, by ordinary mail to the registered H Shareholders who are entitled to receive the Current Final Dividend at their own risk on or around Friday, August 7, 2026.

Details of the 2025 Profit Distribution and the relevant arrangements are set out in the Circular. All Shareholders and investors are advised to read the Circular carefully and consult their advisers if necessary.

(III) ELECTION AND APPOINTMENT OF DIRECTORS OF THE FOURTH SESSION OF THE BOARD

At the AGM, the Shareholders resolved to approve, upon election by the Shareholders attending the AGM, the respective appointments of Dr. LOU Boliang, Mr. LOU Xiaoqiang and Ms. ZHENG Bei as executive Directors of the fourth session of the Board, the appointment of Ms. WAN Xuan as non-executive Director of the fourth session of the Board, and the respective appointments of Ms. LI Lihua, Prof. TSANG King Fung and Ms. SHEN Rong as independent non-executive Directors of the fourth session of the Board. For their biographical details, please refer to the announcement of the Company dated April 28, 2026 and the Circular of the Company dated May 21, 2026. As of the date of this announcement, there has been no change in such information. The employee representative Director of the fourth session of the Board was elected at the employee representative meeting held on June 5, 2026, and together with the non-employee representative Directors elected at the general meeting of Shareholders, constitutes the fourth session of the Board. For the biographical details of the employee representative Director, please refer to the announcement of the Company dated June 5, 2026.

The term of office of the fourth session of the Board will be three years, commencing from the conclusion of the AGM. The number of Directors who also serve as Senior Management and the number of employee representative Directors shall not exceed one half of the total number of Directors and the number of independent non-executive Directors shall not be less than one third of the total number of Directors of the Board. The Company has entered into a service contract with each of the appointed Directors of the fourth session of the Board. The executive Directors and employee representative Director shall not receive any remuneration in their capacities as Directors, but will only receive corresponding remuneration in their respective roles in the Company. Their remuneration for the year ending December 31, 2026 for their respective roles consists of a basic salary plus a performance bonus, of which performance bonus shall in principle account for not less than fifty percent of the total amount of basic salary and performance bonus. Such basic remuneration is determined with reference to similar remuneration standards in the market, taking into account factors such as roles and responsibilities, ability and work location. The basic salary shall be paid on a monthly basis. The performance bonus shall be determined based on the results of individual performance appraisals and the operation of the Company. The non-executive Directors shall not receive any remuneration from the Company. The annual remuneration for independent non-executive Directors is RMB350,000 (before tax) for each independent non-executive Director, which was determined by reference to their roles and responsibilities and prevailing market conditions and shall be paid on a monthly basis. The Company will withhold and pay the applicable income tax on their behalf. The Company shall reimburse the Directors all necessary and actual expenses in relation to the participation of the Board meetings, the Board committee meetings and the general meetings of Shareholders.

(IV) AMENDMENTS TO THE ARTICLES OF ASSOCIATION

References are made to the announcement of the Company dated April 28, 2026; and the Circular and the notice of AGM both dated May 21, 2026. As confirmed by the legal advisers of the Company as to the laws of the People's Republic of China, the Board has obtained the proper authorization from the Shareholders at the AGM to increase in the registered capital and amend the Articles of Association as disclosed in the Circular.

By order of the Board
Pharmaron Beijing Co., Ltd.
康龍化成(北京)新藥技術股份有限公司
Dr. Lou Boliang
Chairman

Beijing, the PRC
June 12, 2026

As at the date of this announcement, the Board of Directors of the Company comprises Dr. LOU Boliang, Mr. LOU Xiaoqiang and Ms. ZHENG Bei as executive Directors; Mr. LI Shing Chung Gilbert as employee representative Director, Ms. WAN Xuan as non-executive Director; Ms. LI Lihua, Prof. TSANG King Fung and Ms. SHEN Rong as independent non-executive Directors.